Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 15/20 | 0.54 |
| ▸ | ITGA2B | P08514 | 15/20 | 0.54 |
| ▸ | F2R | P25116 | 8/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7818397 | 0.94 | ITGB3 (0.59) | ITGB3ITGA2BF2RKDM4EPKM | |
| SCHEMBL6539260 | 0.88 | ITGB3 (0.69) | ITGB3ITGA2BF2R | |
| SCHEMBL7498836 | 0.87 | ITGB3 (0.54) | ITGB3ITGA2BF2RKDM4EPKM | |
| SCHEMBL6538574 | 0.87 | ITGB3 (0.51) | ITGB3ITGA2BF2R | |
| SCHEMBL6936430 | 0.86 | ITGB3 (0.55) | ITGB3ITGA2BF2R | |
| SCHEMBL6937901 | 0.86 | ITGB3 (0.55) | ITGB3ITGA2BF2R | |
| SCHEMBL6539773 | 0.84 | ITGB3 (0.53) | ITGB3ITGA2BF2R | |
| SCHEMBL7440093 | 0.83 | KDM4E (0.56) | ITGB3ITGA2BF2RKDM4EPKM | |
| SCHEMBL6538603 | 0.82 | ITGB3 (0.65) | ITGB3ITGA2BF2R | |
| SCHEMBL7500193 | 0.82 | ITGB3 (0.65) | ITGB3ITGA2BF2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6812235-B2 | 2-ACYLAMINO- BETA -ALANINE DERIVATIVES AND A PHARMACEUTICALLY ACCEPTABLE SALT, USEFUL AS FIBRINOGEN RECEPTOR ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-11-02 | — | — | US | disclosed |
| US-20030018193-A1 | Beta-alanine derivatives and their use as receptor anatgonists | ASTELLAS PHARMA INC. (JP) | 2003-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018193-A1 | Beta-alanine derivatives and their use as receptor anatgonists | ARRB1, ADRB1, GLRB | ITGB3 423/4885ITGA2B 346/4885F2R 1250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.